probenecid has been researched along with Ataxia in 3 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
Ataxia: Impairment of the ability to perform smoothly coordinated voluntary movements. This condition may affect the limbs, trunk, eyes, pharynx, larynx, and other structures. Ataxia may result from impaired sensory or motor function. Sensory ataxia may result from posterior column injury or PERIPHERAL NERVE DISEASES. Motor ataxia may be associated with CEREBELLAR DISEASES; CEREBRAL CORTEX diseases; THALAMIC DISEASES; BASAL GANGLIA DISEASES; injury to the RED NUCLEUS; and other conditions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The possibility that non-sedating antihistamines could elicit sedation in mice due to drug-induced inhibition of brain PgP was evaluated by measuring the ability of desloratadine alone or in combination with verapamil to cause ataxia in mice." | 3.74 | Verapamil, but not probenecid, co-administration can convert desloratadine to a sedating antihistamine in mice. ( Bachmann, K; Bykowski, C; Dhananjeyan, M; Erhardt, P; Hacker, M; Katta, A; White, DB, 2007) |
| " Coadministration of the transport inhibitor probenecid (p-(dipropylsulphamoyl)-benzoic acid) enhanced and prolonged the anticonvulsant action of NBQX and also enhanced and prolonged ataxia." | 3.68 | Probenecid pretreatment enhances anticonvulsant action of NBQX in mice. ( Taylor, CP; Vartanian, MG, 1992) |
| "Animal models of Parkinson's disease have been widely used for investigating the mechanisms of neurodegenerative process and for discovering alternative strategies for treating the disease." | 1.35 | Restorative effect of endurance exercise on behavioral deficits in the chronic mouse model of Parkinson's disease with severe neurodegeneration. ( Kurz, MJ; Lau, YS; Pothakos, K, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Pothakos, K | 1 |
| Kurz, MJ | 1 |
| Lau, YS | 1 |
| Katta, A | 1 |
| Dhananjeyan, M | 1 |
| Bykowski, C | 1 |
| Erhardt, P | 1 |
| Hacker, M | 1 |
| White, DB | 1 |
| Bachmann, K | 1 |
| Taylor, CP | 1 |
| Vartanian, MG | 1 |
3 other studies available for probenecid and Ataxia
| Article | Year |
|---|---|
Restorative effect of endurance exercise on behavioral deficits in the chronic mouse model of Parkinson's disease with severe neurodegeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amphetamine; Animals; Ataxia; Disease Models, Animal; | 2009 |
Verapamil, but not probenecid, co-administration can convert desloratadine to a sedating antihistamine in mice.
Topics: Animals; Ataxia; ATP Binding Cassette Transporter, Subfamily B, Member 1; Brain; Chromatography, Liq | 2007 |
Probenecid pretreatment enhances anticonvulsant action of NBQX in mice.
Topics: Animals; Anticonvulsants; Ataxia; Drug Synergism; Injections, Intravenous; Male; Mice; Motor Activit | 1992 |